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Abstract
Food allergy appears to be on the rise with the current mainstay of treatment centred on allergen avoidance.
Mandatory allergen labelling has improved the safety of food for allergic consumers. However an additional form of
voluntary labelling (termed precautionary allergen labelling) has evolved on a wide range of packaged goods, in a bid
by manufacturers to minimise risk to customers, and the negative impact on business that might result from exposure
to trace amounts of food allergen present during cross-contamination during production. This has resulted in near
ubiquitous utilisation of a multitude of different precautionary allergen labels with subsequent confusion amongst many
consumers as to their significance. The global nature of food production and manufacturing makes harmonisation of
allergen labelling regulations across the world a matter of increasing importance. Addressing inconsistencies across
countries with regards to labelling legislation, as well as improvement or even banning of precautionary allergy labelling
are both likely to be significant steps forward in improved food safety for allergic families. This article outlines the current
status of allergen labelling legislation around the world and reviews the value of current existing precautionary allergen
labelling for the allergic consumer. We strongly urge for an international framework to be considered to help roadmap a
solution to the weaknesses of the current systems, and discuss the role of legislation in facilitating this.
Keywords: Allergen labelling, Food allergy, Legislation, Precationary allergen labelling, Anaphylaxis, Allergen avoidance,
Mandatory labelling
Introduction
Avoiding specific foods and ingredients to which
patients are allergic poses an important health challenge,
especially in view of the increase in prevalence of food
allergies in both developed and developing countries
[1-8]. With the rising growth and development of
worldwide manufacturing and more efficient ways to
transport products at low cost around the world, what
we now eat is increasingly provided by a food bowl that is
global in scope (see Box 1). This has a significant impact
on both food quality and safety, as different countries are
governed by different manufacturing regulations and
guidelines. There is a wide disparity between developed
and developing countries with regards to the control
and regulation of food labelling [9], and even among
developed countries significant differences exist. This
is of major importance to those with food allergies, who
need to know with a high degree of certainty whether or
not a food they consume contains an allergen, perhaps as
a result of cross-contamination during production, and
is therefore likely to trigger an adverse reaction. This
paper aims to provide evidence regarding the variation in
government guidelines and regulatory oversight of
food labelling with particular focus on the vexed issue of
precautionary allergen labelling. We discuss how a globally
systematic and harmonized approach to food labelling will
benefit consumers, regulators and manufacturers alike.
Case Study
In December 2010/January 2011, at least 6 peanut-
allergic individuals experienced significant allergic reac-
tions after eating a variety of seafood products in
geographically-distinct areas in Australia. The products all
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contained a crumb coating, supplied by a company in
Beijing, China, which in turn contained soy flour supplied
by a third party company. It is believed that the supply
chain for the soy flour involved a number of companies,
one of which had changed its production line resulting in
contamination from peanut flour. This case demonstrates
the difficulty in allergen-tracing along the supply chain
and the increasing tendency to source raw ingredients
from abroad. [http://allergenbureau.net/march-2011-news-
round/].
What are the various types of mandatory food labelling
relating to food allergens?
In 1999, the World Health Organisation Codex Alimen-
tarius Commission established guidelines for all countries
that outlined the main 8 foods that should be considered
for allergen labelling [10]. Subsequently, food labelling
legislation has been introduced in many other countries,
as outlined in Table 1. In general, allergen labelling can be
divided into 2 categories:
1) Labelling of allergens that are present in the
ingredients and used in the production of the food.
Legislation mandating labelling of allergenic
ingredients has now been introduced in a large
number of countries (Table 1). Most developed
countries mandate labelling of the most common
allergenic foods such as peanuts, tree nuts, milk,
eggs, fish, crustacea/shellfish, soy and wheat or
cereals containing gluten, as well as ingredients
derived from those foods in accordance with the
1999 Codex Alimentarius Commission guidelines.
However, there are significant differences between
countries as to what allergens are required to be
disclosed, and the manner in which this is
communicated to the consumer. Many countries
recommend two methods, either highlighting the
presence of an allergen in the ingredients list itself,
or as a separate ‘contains X’ statement for allergenic
ingredients. Within the European Union (EU) both
methods are currently permitted but only the first is
mandatory. From December 2014, the latter will be
prohibited [26], presumably as a means to encourage
consumers to study ingredients lists themselves
rather than rely on optional non-mandatory
statements which may be incomplete.
The list of specific allergens that require mandatory
declaration often varies between countries. Most,
but not all, include the 8 allergens proscribed by the
Codex – Japan is a notable exception, where the
pattern of food allergy is different from elsewhere
and consequently, mandatory disclosure is limited to
those allergens which are prevalent locally [18].
There are also differences in the definition of
allergen categories, particularly tree nuts: within the
EU, pine nuts are considered to be seeds, but are
classified as a tree nut in USA and Canada. In the
USA, several additional products are considered tree
nuts, including coconut, shea nut and lychee. Some
of these are not tree nuts botanically: coconut palms
are not trees but ferns; lychee is a fruit and not a
nut. The declaration of molluscs is also variable,
with some countries classifying this as a ‘fish’ while
in others, the inclusion is not clear (see Table 1).
The mandatory disclosure of food allergens is not
exclusive to developed countries; a significant
proportion of countries in Latin America now
require mandatory labelling, including: Argentina,
Bolivia, Brazil, Chile, Colombia, Costa Rica, Cuba,
Mexico, Nicaragua and Venezuela. In the Far East
and Asia, countries that have legislated allergen
disclosure include Malaysia, South Korea, Japan, and
Singapore. India is currently considering mandatory
disclosure. China introduced legislation in 2012,
perhaps in part due to the wide export of food
products to countries where mandatory disclosure is
required. The ‘policing’ and monitoring of allergen
disclosure can vary from country to country
(including ‘developed’ countries), and is poorly
described in the literature.
In most countries with mandatory allergen labelling,
disclosure is only required for pre-packed foods. From
December 2014, legislation is being introduced
throughout the European Union which will require the
mandatory disclosure of allergens in non-pre-packed
foods purchased for example from bakeries, butchers,
and catering outlets, such as fast-food outlets and
delicatessens [26]. Of note, the new legislation does
not extend to potential contamination with allergens
during production. However the requirement to
manage potential contamination with a view to
protecting allergic consumers is covered through
European Commission Regulations 178/2002 and
852/2004. The legislation requires that manufacturers
have to take account of the special needs of minority
groups such as individuals with food allergies.
2) Precautionary statements relating to allergens
which might be present due to cross-contamination
during food production. Foods can become
contaminated with residues of allergenic foods at
many points along the food chain (Figure 1), and
different products may be produced on shared
equipment, some containing allergenic ingredients
and others not [27]. This may pose relevant health
risks to those with food allergies. Uncertainty over
the risk posed to allergic individuals by even very
minute residual amounts/traces of allergen has
prompted many food manufacturers to provide
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advice as to the potential for unintentional
contamination with allergens during manufacture in
the form of precautionary allergen labelling (PAL),
also known as “may contain” statements. However, in
the vast majority of countries, the use of PAL is not
regulated by legislation (Table 2), and it is suspected
that in many cases, a formal risk assessment is not
performed to guide the use of PAL.
While PAL might be conceived as a useful strategy to
convey risk of allergen cross-contamination, in practice
their use has generated considerable uncertainty over their
meaning [30]. A number of workshops have been held
between different stakeholders, including industry, to drive
good practice towards developing a standardised approach
to allergen risk assessment and the use of PAL [31,32].
However, application of PAL remains inconsistent across
industry and products, i.e. it does not represent a defined
risk that can be communicated to consumers and other
stakeholders. Furthermore, it is suspected that some
manufacturers use PAL as an alternative to allergen
risk management, rather than as a means to communicate
the actual risk of cross-contamination following a risk
assessment and intervention to minimise risk according to
Good Manufacturing Practice (GMP).
How common is the use of precautionary allergen
labelling?
Studies have shown a high prevalence of PAL. A survey
commissioned by the UK Food Standards Agency (FSA)
in 2001 assessed the prevalence of PAL in an ‘average’
shopping basket of 232 food items. The survey reported
that 69% of cereals and 56% of confectionery items were
labelled as containing ‘traces’ of nuts, despite none listing
peanut or tree nuts as an ingredient [33]. A more extensive
survey of over 20,000 unique products from 99 supermar-
kets in the United States found that 17% had PAL [34]. In
the category of certain convenience foods, such as cookies
and confectionery items, the rate exceeded 50%. The study
also disclosed 25 different labelling terms used to indicate
potential inclusion of the allergen, with PAL that
could be classified into 3 broad categories: “may contain…”,
“produced on shared equipment…” and “made in the same
factory as…” (Figure 2). A similar observation has been
made in a survey of 1355 supermarket products in
Australia, where 65% of items included a precautionary
statement of some sort [35].
Do allergic consumers heed precautionary allergen
labelling statements?
Avoidance of foods with PAL places an additional burden
on the allergic consumer, with a survey reporting that
shoppers avoiding products with PAL spending 39% more
time identifying suitable foods, and paying on average
11% more than their non-allergic counterparts [33].
The widespread use of PAL causes considerable confusion
and anxiety to people with allergies and their caregivers,
and it is not uncommon for consumers to miss allergy
warnings altogether [33,36,37]. The use of different
wording on PAL statements is confusing and may
Figure 1 Potential sources of allergen contamination/cross contact during food production (Source: UK FSA).
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contribute to the increasing trend for consumers to
ignore them altogether [38,39].
A survey of young food-allergic adults in the USA in
2006 reported that over 40% ignored PAL [40]. Hefle
et al. conducted a similar survey assessing consumer
views prior to and after the introduction of new food
labelling legislation in the USA, with over 600 individuals
questioned during the 2003 and 2006 Food Allergy &
Anaphylaxis Network conferences in the USA [39]. These
participants might be expected to demonstrate increased
concern over exposure to ‘trace’ amounts in foods with
PAL, but surprisingly, 25% of participants in 2006 admit-
ted to ignoring some PAL. The majority avoided foods la-
belled “may contain” but many assumed that statements
such as “shared facility” implied a lower level of risk. A
UK based survey found that 60% of parents of children
with nut allergies avoided products labelled “may contain
traces,” but only 40% did so when less direct statements
were used – for example, “made in a factory that uses
nuts” [41]. Similar findings have been reported in Japan
[42], Canada [43] and Australia [44], suggesting that the
more ambiguous the warning, the less likely con-
sumers are to heed the content. Furthermore, there is
evidence that consumers are ignoring PAL irrespective of
whether they have a history of prior anaphylaxis – patients
who might be expected to be more cautious with avoid-
ance of foods with PAL [45].
Barnett et al. investigated the process through which
32 peanut- and nut-allergic adults interpreted PAL when
purchasing food [46]. Only 3 (9%) were clear in their claim
to judiciously avoid all foods with PAL. Many claimed
such labelling was not credible or desirable, using 1 or
more of 4 main strategies:
1) PAL is so prevalent that one cannot avoid eating
food products with them
2) PAL was seen as being used to ‘protect’ the
manufacturer from any claims arising from an
allergic reaction due to cross-contamination
3) More ‘wordy’ PAL was interpreted as implying a lower
risk, and could therefore be consumed by those who
avoided products with more direct “may contain” labels.
4) Implausibility, when, for example, PAL to nuts
appeared on a packet of peanuts, the implication
being that PAL are not rationally or reliably applied
by manufacturers.
Interpretation and consequent decisions were not only
based on the detail of the labelling but also on external
factors such as the nature of the product, any discounts
on the product, the perceived trustworthiness of the
producer and on the previous experience of the nut allergic
individual (e.g. if they had already bought and consumed
products with this type of labelling with no reaction). Some
consumers would ignore the PAL if they ‘liked’ the food
product and they felt that any consequential reaction
would only be mild in severity.
Recent years have seen a growing awareness of these
issues among the clinical community, although practice
varies about the advice given to patients on whether
foods with PAL are safe for them [47]. Clearly, health
professionals charged with advising the allergic consumer
are faced with the same issues as the consumer when
interpreting the current situation. International efforts to
define threshold levels of allergens along with validated
allergen detection methods are essential to address these
problems at a policy level.
Does the use of precautionary allergen labelling
correspond with risk of allergen exposure?
Relatively few studies have been conducted to evaluate
the risks posed by allergen residues in pre-packed foods,
Figure 2 Examples of advisory warnings found on food labels.
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and whether these correspond to the presence of PAL. The
available data are summarised in Figure 3 from studies
during the recent period 2006–2012 when improved
allergen detection has become available [39,45,48-53].
These studies are subject to unavoidable methodological
limitations, in that most did not assess batch-to-batch and
within-batch variations in allergen content (with the
exception of Zurzolo et al. [45]), and many only sampled a
small number of the available products. Nonetheless, it is
clear that the vast majority of foods with PAL did not
contain evidence of allergen contamination.
Some studies also assessed the presence of allergen
contamination in food products without PAL. Pele et al.
analysed 544 food products (cookie biscuits and chocolates)
for peanut content from 10 European countries in 2006
[49]. While 32% of products with PAL were found to have
peanut contamination, 25% of items without PAL had
evidence of peanut contamination. Ford et al. found
allergen contamination (milk, egg, or peanut) in 5.3%
of products with PAL compared to 1.9% of products
without [53]. Notably, peanut was not detected in any of
the 120 products tested that had no PAL. It is thus possible
that the risk of peanut contamination is reducing over time
as awareness within the food industry increases. In Ireland,
11% of 106 food products without PAL contained
undeclared allergen, compared to 6.5% of 108 products
with PAL [52]. Thus, the absence of PAL does not imply a
food is safe for consumption by allergic individuals; this is
poorly communicated to both allergic consumers and
healthcare professionals alike.
Biochemical analysis of foods (mostly using ELISA
based assays) have demonstrated that there is little
correlation between the wording of the PAL and the risk
of cross-contamination [39,48,49,51]; indeed, one USA
study found that the rate of contamination was higher
when the PAL stated “prepared in a shared facility” than
when the label read “may contain” or “produced on shared
equipment” [39]. However, differences in detection of
allergens in such studies is confounded by variations in
the quality of the analytical methods used which compli-
cates interpretation of results [54]. Allergic consumers
(and their families) may interpret ‘tolerance’ of food items
with PAL as a sign of a more ‘mild’ food allergy, which
can result in less stringent allergen avoidance. The wide-
spread use of poorly defined labelling has resulted in a loss
of credibility which might, paradoxically, lead to increased
risk taking.
What is the actual risk to the allergic consumer?
The risk to the allergic consumer in eating a product
which may contain allergen due to cross-contamination
is not solely related to the amount of allergen potentially
present in that item. It also depends on the amount of
the product consumed and the amount of allergen
needed to trigger a reaction in that particular individual,
known as an eliciting dose (ED). Data relating to the
former can be estimated from national surveys of food
consumption, while eliciting doses can be determined
from published series of food challenges (known as
population thresholds). However, many countries lack
these data and the absence of thresholds relating to
genetically diverse populations represents a clear deficit in
the literature.
Studies involving double blind, placebo-controlled food
challenges have demonstrated that allergic individuals react
to a range of allergen amounts, with often a 4–5 log-fold
difference between the ‘most’ and ‘least’ sensitive subjects
[55], although the stopping criteria used to determine these
0 10 20 30 40 50 60
Hefle et al, 2007
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Pele et al, 2007
(n=569) Europe
Ford et al, 2010
(n=228) USA
Crotty et al, 2010
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FSAI, 2011
(n=108) Eire
Remington et al, 2013
(n=352) USA
Zurzolo et al, 2013
(n=128) Australia
Robertson et al, 2013
(n=38) Eire
% pre-packed food products with PAL containing allergen
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Hazelnut
Soya
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Egg
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Figure 3 Prevalence of allergen cross-contamination in prepacked foods with PAL. (* Note: Zurzolo et al. also assessed products for milk,
egg, hazelnut and soya; these allergens were not detected in any product [45]. The higher rates of allergen detection in surveys by Crotty et al.
[48] and Pele et al. [49] are most likely due to the food products included: dark chocolate and cookie biscuits/chocolate respectively).
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reaction thresholds are not always consistent. This has
improved of late with the use of internationally-agreed
criteria based on objective symptoms [56,57]. The actual
allergen dose to which individuals react varies with a
whole host of poorly-understood factors, including the
nature of the product in which the allergen is contained
(known as the food matrix) and a range of factors specific
to the individual (for example, intercurrent viral infec-
tions) [30]. Furthermore, the most sensitive individuals
are often excluded from food challenges due to safety
concerns. Nonetheless, using statistical modelling, it is
possible to determine the ED01, ED05 and ED10
doses for specific allergens (these are the eliciting
doses to trigger reactions in 1%, 5% and 10% of the
allergic population, respectively), which can then be
used in risk prediction.
This method was used in two reports published in 2013.
The first, by the team at the Food Allergy Research &
Resource Program in Nebraska, USA, used a probabilistic
risk assessment which estimated the probability of a
reaction in peanut-allergic consumers from nutrition
bars with PAL to peanut in USA to be between 2 and 10
predicted reactions per 1000 eating occasions, although
this was probably as over-estimate of the actual risk;
this translates into 0.8–1.1 reactions per 100,000
peanut-allergic individuals per day [51]. A second report,
by the same team, evaluated the prevalence of cross-
contamination in Ireland, by assessing allergen content
in 38 pre-packed foods with PAL, 92% of which were
confectionery or snack items [50]. Two (5%) were
found to have peanut contamination (a chocolate bar
and a cereal bar); taking into consideration the level
of contamination and serving size, this translated into
an estimated risk of 2.6 predicted reactions per 1000
eating occasions. While this implies that the vast majority
of food products with PAL to peanut will be tolerated by
most peanut-allergic individuals, there is a small risk of
allergic reactions to these foods.
Given that many allergic individuals do not heed PAL
and consume foods with PAL [39-44], it is perhaps
surprising how few reports there are in the literature of
reactions attributed to an allergen present in foods due
to cross-contamination. Very few studies have attempted
to systematically investigate causes of accidental reac-
tions in allergic individuals and there is a clear need for
further data to be collected at the population level.
Sheth et al. described 651 food-allergic patients on a
Canadian registry who experienced an allergic reaction
due to inadvertent allergen exposure, and reported on the
patients’ opinions as to the cause of their reaction
[37]. Almost half attributed the reaction due to a
labelling-related issue: 8.7% of reactions were attributed to
failure to heed a PAL, while 16.6% blamed the reaction on
the absence of a PAL in the presence of presumed
cross-contamination. However, there is little published data
relating to allergic reactions due to cross-contamination
that have been substantiated by biochemical analysis of the
food in question [58,59], and it is therefore difficult to
determine how common reactions due to unintentional
cross-contamination are, in reality.
Improving the utility of precautionary allergen labelling
Some countries have taken steps to reduce the variety
of labelling that should be used as PAL. For example,
in 2006, the UK Food Standards Agency produced a
comprehensive guide to best practice that recommends a
non-quantitative approach to determining risk of allergen
cross-contamination [27]. Although the guideline recom-
mends uniform wording of advisory warnings, the advice
is voluntary and has done little to reduce the prevalence
and variety of PAL currently used in the UK [57]. Under
new EU legislation, to be introduced from December
2014, allergen disclosure will be clearer within ingredients
lists and separate ‘contains’ statements will no longer be
permitted [26], but PAL will continue to fall outside the
remit of legislation. Canada modified food labelling
legislation in 2012, and now requires allergens (as actual
ingredients) to be declared using common names
(e.g. milk, rather than “casein”) among other measures,
which is consistent with legislation in Australia, EU and
the USA. However, disclosure of allergens which may
be present due to cross-contamination, (using PAL
statements) remain voluntary and unregulated, although
the regulatory authority now recommends that only a
single phrase - “may contain:” - is used [14].
The use of PAL is currently regulated in 4 countries –
Switzerland, Japan, Argentina and South Africa.
Switzerland
The first country to utilise a threshold to guide the use
of PAL was Switzerland in 2000 [29]. No labelling is
required at levels below 10 mg/100 g (100 ppm) gluten
for cereals or 1 g/kg (1000 ppm) for other allergens.
However, this equates to a protein level of 100 mg in a
100 g serving for non-gluten allergens, a level predicted to
cause an allergic reaction in up to 50% of peanut-allergic in-
dividuals [55]. Unfortunately, there are no data assessing the
impact of this threshold on the incidence of allergic reac-
tions. The legislation in Switzerland (which does not belong
to the EU) is otherwise similar to that of the EU, with the
additional stipulation that while PAL are permitted, they
can only be used with regards to allergen presence result-
ing from cross-contamination where that allergen has
been shown to be present above these threshold levels.
Japan
In 2002, mandatory food allergy labelling became regulated
under Japanese law [18]. At the same time the use of “may
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contain” statements was strictly prohibited; a threshold of
10 microgram protein/g food weight (10 ppm) was
established, above which mandatory labelling for the
above allergens is required, irrespective of whether
that allergen was intentionally present as an ingredient or
due to cross-contamination. Manufacturers are required
to use specified methods (ELISA, PCR, Western blot) to
determine the need for allergen disclosure although there
is little data as to how this requirement is monitored. The
presence of allergen in quantities below 10 ppm does not
require disclosure. However, alternative declarations, such
as “this product contains minute amounts of X” or “made
in a factory that produces products that contain” are
permitted, and may be used by manufacturers to alert the
consumer as to potential allergen cross-contamination. It
has been suggested that these labels may be used to reflect
a higher quality of food to the consumer: seafood, for
example, is widely perceived to have health benefits
and so foods ‘produced in the same factory’ might
indicate a product of superior quality to the Japanese
public (R Crevel, personal communication).
The Ministry of Health, Labour and Welfare (MHLW) of
Japan was the first government body to provide a definition
of a ‘trace’ allergen amount requiring disclosure and to
regulate this by law, through the use of allergen detection
assays. In so doing the Japanese government has recognised
that zero tolerance of allergenic foods may be unrealistic.
Not only has the Japanese government set threshold limits
for allergens in food, but they have limited the use of PAL
with the aim of protecting the allergic consumer. The
threshold of 10mcg/g was chosen on the basis that while
the use of thresholds for the management of allergens could
be of considerable value to all stakeholders, data were
largely considered inadequate to derive them in the past
[60]. As an alternative, it was felt that “if more than a few
micrograms of protein weight per ml of food or a few mi-
crograms of protein per gram of food are contained in a
food, labelling of that allergen is necessary” on the basis
that this might result in an allergic reaction [18]. This as-
sumes, therefore, that amounts under these levels are un-
likely to result in an allergic reaction. However, this may
not be true, at least in theory. A threshold of 10mcg/g
threshold means that in practice, an allergic consumer
would need to eat 1 kg of a food product to be exposed to
10 mg of allergen, a serving size greater than that which
would normally be expected. However, as can be seen in
Table 3, the ED01 and even ED10 for some allergens
are under 10 mg. For example, a hazelnut-allergic
person could, in theory, expose themselves to a food
containing less than 10mcg/g allergen (and thus have
no allergen disclosure on the label); in this scenario, a
serving of just 10 g could contain sufficient allergen to
trigger an allergic reaction in 1 in 100 hazelnut-allergic
individuals. Similarly, for cow’s milk, a threshold of
10mcg/g might not be protective for up to 1 in 10
milk-allergic children, a proportion which we consider
to be significant. However, little is known of the rate
of allergic reactions due to undisclosed allergens, industry
compliance with the need for analysis or the impact
the regulations has had on purchase habits and quality of
life measures of the allergic consumer. This data would
help to validate Japan’s decisions regarding mandatory and
precautionary labelling.
Argentina
More recently, Argentina introduced legislation in 2010,
which prohibited the use of all PAL [11]. Food labelling
must be clear, thus an allergen is either ‘present’ or absent.
Manufacturers appear to be permitted to use “Contains
X” statements to list allergens which might be present
due to cross-contamination, irrespective of whether
the allergen is actually present or not.
South Africa
South Africa recently introduced legislation which permits
the use of PAL, but manufacturers need to demonstrate the
Table 3 Ministry of Health, Labour and Welfare (MHLW) of Japan threshold limits for allergen disclosure, and how
these relate to serving size and (European) population thresholds
Population threshold (mg protein) [61-63] Minimum serving size not requiring allergen disclosure under Japanese
legislation that could contain sufficient protein to cause a reaction in:
ED01 [61,62] (mg protein) ED10 [63] (mg protein) 1% of allergic individual 10% of allergic individual
Peanut 0.2mg 2.8mg 20g 280g
Cow’s milk 0.1mg 0.1mg (<3.5 yrs) 10g 10g (<3.5 yrs)
5.3mg (>3.5 yrs) 530g (>3.5 yrs)
Egg 0.03mg 0.6mg (<3.5 yrs) 3g 60g (<3.5 yrs)
20.4mg (>3.5 yrs) 2kg (>3.5 yrs)
Hazelnut 0.1mg 8.5mg 10g 850g
Soya 1.0mg n/a 100g n/a
Wheat 1.0mg n/a 100g n/a
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potential presence of allergen due to cross-contamination
despite adherence to Good Manufacturing Practice
(GMP) through a documented risk assessment; use of
PAL is otherwise prohibited [23].
Is there an alternative to legislation and regulation?
The Voluntary Incidental Trace Allergen Labelling (VITAL)
initiative developed by the Australian food industry’s
Allergen Bureau represented a first attempt to introduce a
formal and transparent basis for of risk assessment by
manufacturers in the application of PAL [64]. The VITAL
process was developed with the intent of replacing
all other forms of precautionary labelling, using a
validated risk assessment tool to determine the need
for precautionary labelling.
Under VITAL, the manufacturer performs a risk
assessment using the VITAL calculator which has
been designed to alert the manufacturer of the possible
presence of sufficient levels of allergen residues arising
from cross contact and based upon analysis to provoke
allergic reactions in consumers ingesting specified
quantities of these products [65]. Once the manufacturer
receives the raw material, the product information form
(PIF) which provides specification of other information
from the supplier for each ingredient is reviewed and a
decision is made for each cross contact allergen. The
manufacturing line and environment are then reviewed to
determine if there are any cross contact allergens
which may become incorporated in the product in the
manufacturing process. The VITAL calculator then
determines the final allergen content and compares
this to Reference Doses which were defined for major
allergenic foods. The initial VITAL action levels were
based on minimum eliciting doses for regulated allergenic
foods (expressed as doses of protein) collated by the 2006
U.S Food & Drug Administration (FDA) Threshold
Working Group [66]. Initially, due to limited data on
minimum provoking doses existing at that time, a 10-fold
uncertainty factor was applied by VITAL to assure that
sufficiently conservative action levels were promulgated.
VITAL was recently revised (VITAL 2.0) following an
expert panel review of threshold data [62], and no longer
incorporates an uncertainty factor as the thresholds
selected are deemed to be tolerated by 95 - 99% of the
allergic population (see Table 3). There are now two
actionable levels: if an item falls within Action Level One
it requires no precautionary statement and the food is
regarded as safe to eat by the allergic consumer. If the
product falls within Action Level Two, VITAL “may be
present” statement is used. VITAL Action Level Two is
used for allergens in particulate form (a separate and
distinct particle of material e.g. sesame seed). If present
in the final product as a readily dispersible allergen (a
powder or liquid in a homogenous form) the total
protein concentration from the allergen source is deter-
mined and labelled according to mandated regulations.
Importantly, under VITAL, only a single distinct precau-
tionary statement – “may be present” – is to be used, to
avoid the confusion which has resulted from multiple
phrases used in PAL. The aim was that the appearance of
this statement would imply that a VITAL assessment had
been performed.
While interest from industry has been enthusiastic,
actual implementation of the process has been more
limited to date [35], which might be seen as a conse-
quence of the voluntary nature of the scheme. Another
shortcoming is that not all of the foods which have been
subject to the VITAL assessment are identifiable to the
consumer. Products that have been through the VITAL
process and are found to be Action Level one do not
carry a label and therefore an allergic consumer cannot
distinguish that this food product is likely to be safer than
one that has no label but not subjected to VITAL. This is
currently the greatest limitation of VITAL 2.0 with
respect to usefulness to the consumer as in essence it
is an educational tool for manufacturers to ensure appro-
priate allergen risk management. Furthermore the meas-
urement of actual allergen levels are not required as part of
VITAL, although when contamination is suspected over
and above that of Action Level two manufacturers usually
send samples for analytical assessment and to reassess the
manufacturing process and risk of contamination.
While validation of the assessment can be performed
through analysis of the food products for allergen
cross-contamination, this is not mandatory due to the
inherent limitations of allergen detection [54]. Importantly,
VITAL and indeed all PAL does not cover the occurrence
of an accidental contamination with large pieces of particu-
late matter such as a whole nut.
Limitations of allergen detection methods for use by
manufacturers
Controversies remain regarding the most valid and precise
form of allergen detection [54]. Unfortunately the
more reliable and precise the methodology the more
likely it is to be cumbersome and cost-prohibitive and
as such manufacturers often rely on less validated kit
methodologies. Similarly, public health agencies in various
countries have not provided guidance to industry on pre-
ferred approaches and as yet there is no universally-agreed
method for allergen detection.
Sampling strategies remain another area of concern
and uncertainty. The allergen residues in homogeneous
foods, such as ice cream, are more likely to be uniformly
distributed and sampling is a lesser issue. In other cases
such as with particulate contamination especially, the num-
ber and selection of samples becomes critical to improve
reliability for detecting allergen contamination [67]. Due to
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the uneven distribution of the allergen the ability to detect
allergen becomes extremely variable. As yet there are no
currently agreed industry standards on sampling for
particulate contamination.
Is there a role for legislation in establishing a global
system for precautionary allergen labelling?
Establishing a system for PAL which is globally accepted
and used widely means not only that industry itself can
improve its practices and therefore food safety, but also
provides the opportunity for better communication and
management of allergen risks by clinical practitioners and
their patients and thereby improves allergy management
and food choices. However, should this be done through a
legislative approach (as in Japan) or through voluntary
measures? The 2006 guidance released by UK Food
Standards Agency on best practice with regards to PAL
had minimal impact on the utility of such labelling in the
UK [57]. Indeed, in a subsequent evaluation of the 2006
guidance, almost two thirds of enforcement officers and
large food producers surveyed felt the guidance should be
compulsory [68]. While regulation may be tempting, there
are a number of drawbacks to this. Legislation requires
certainty – for example, legislation based on allergen
analysis must consider the inherent problems in allergen
detection (discussed above), and the need to use an appro-
priate detection method for different forms of the allergen
(and where no appropriate allergen detection method, nor
reference material exists) [54]. Significant research gaps
remain in both the robustness of allergen detection tech-
niques and clinical reactivity thresholds, as reviewed else-
where [69]. Regulation may also result in a lack of
flexibility to adapt to new methods of allergen detection
and even new information relating to allergen thresholds
as more data become available. These drawbacks need to
be balanced against a possible need to use regulation
to drive improvements in food allergen labelling.
In this article, we have reviewed the current situation in
many countries, which does not benefit either the allergic
consumer or food manufacturers who are potentially liable
for an allergic reaction resulting from cross-contamination.
Those countries which have introduced legislation based
on allergen thresholds (i.e. Japan and Switzerland) with
regards to PAL may have improved the usefulness of
such labelling to the allergic consumer, but further
data are needed to substantiate this. We suggest that
legislation will be required to introduce uniformity
amongst manufacturers in conducting a risk assessment
for allergen content and then communicating that risk in
an easily understandable way to the allergic consumer.
Figure 4 Can regulation improve precautionary advisory labelling? Legislation may be required to introduce uniformity amongst
manufacturers in conducting a risk assessment for allergen content and then communicating that information to the allergic consumer. However,
regulation has its weaknesses and needs to be balanced against the ability of a system to adapt to new technologies (e.g. in allergen analysis)
and clinical data (e.g. updated allergen thresholds). Once established, ongoing improvements to PAL may be best achieved through a less rigid
legislative process (depicted by the dotted line in the figure).
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However, regulation through the legal system also has its
weaknesses and therefore needs to be balanced against the
ability of any system to communicate risk of allergen
cross-contamination to adapt to new technologies and
clinical data. This may best be achieved in the long run
through a balance between self-regulation and manufac-
turing legislation (Figure 4). With the growing burden of
food allergies it is clear that food labelling should become
a priority amongst policy makers and health authorities.
Importantly, improved determination of reliable thresh-
olds would better inform calculation of risk and therefore
remain priorities for further research. Until now allergen
threshold predictions have relied on data from oral food
challenges that have employed protocols where up-dosing
at regular intervals occurs until a single serve equivalent is
tolerated or an allergic reaction intervenes. Although food
challenges are the gold standard for the diagnosis of
IgE-mediated food allergy, the precision around which
dose the patient has reacted to is diminished because
the intervals between up-dosing are usually 15–30
minutes for practical reasons – i.e. to minimise the
impact on time spent doing the challenge when up to 7
doses need to be administered. As such it is not always
clear whether the patient is reacting to the most recent
dose, a preceding dose or to an overall cumulative dose.
To counteract these limitations there are several single
dose studies in preparation or underway to better
delineate the lower values of the threshold curves.
Zurzolo et al. [70] have initiated a multicentre trial in
peanut allergic children to confirm or refute the currently
determined ED05 (eliciting dose for 5% of the peanut
allergic population). Studies such as these will help inform
more reliable threshold predictions which will enable
manufacturers to better predict the safety of their food.
Are we ready for a global framework with regards to
precautionary allergen labelling?
Precautionary allergen labelling remains a vexed issue for
allergy consumers and clinicians alike. There is clearly an
unmet need with regards the value of current PAL
standards and utility and a clinical imperative to remove
the burden of risk from the allergic consumer. A globally
agreed framework would enable progress to be made to
ensure that foods produced around the world can be
safely ingested by consumers irrespective of allergy status.
A globally relevant framework would enable careful
consideration of issues such as should manufacturers
universally implement risk assessment tools (e.g. VITAL 2.0
as in Australia) or whether governments should consider
setting mandated thresholds and ban precautionary allergen
labelling (as in Japan). Could such a framework embrace
the differential complexities of manufacturing in developed
versus developing countries and the potential difference in
threshold levels for different populations? Could a global
framework assist in engendering consensus on the most
reliable and cost-effective allergen detection assays for
international application? At the very least, international
consistency of the types of statements employed for PAL
would be a significant early step forward for improved
utility and safety for the allergic consumer. Harmonisation
of allergen regulations across the world will be important
to both protect allergic consumers and help support
effective trade in the global market place.
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